Search Results - "Caballol, B"

Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU by Mesonero, F., Zabana, Y., Fernández-Clotet, A., Solá, A., Caballol, B., Leo-Carnerero, E., García, M.J., Bertoletti, F., Bastida, G., Suris, G., Casis, B., Ferreiro-Iglesias, R., Calafat, M., Jiménez, I., Miranda-Bautista, J., Lamuela, L.J., Fajardo, I., Torrealba, L., Nájera, R., Sáiz-Chumillas, R.M., González-Partida, I., Vicuña, M., García-Morales, N., Gutiérrez, A., López-García, A., Benítez, J.M., Rubín de Célix, C., Tejido, C., Brunet, E., Hernandez-Camba, A., Suárez, C., Rodríguez-Lago, I., Piqueras, M., Castaño, A., Ramos, L., Sobrino, A., Rodríguez-Grau, M.C., Elosua, A., Montoro, M., Baltar, R., Huguet, J.M., Hermida, B., Caballero-Mateos, A., Sánchez-Guillén, L., Bouhmidi, A., Pajares, R., Baston-Rey, I., López-Sanromán, A., Albillos, A., Barreiro-de Acosta, M.

“…Inflammatory pouch disorders exhibit a heterogeneous clinical spectrum and therapeutic requirements have not been properly studied. This retrospective,…”
Get full text

P276 Predictive value of changes in 3D volumetry in perianal fistulas in patients with Crohn’s disease under biologic therapy. A pilot study by Ordás Jiménez, I, Caballol, B, Saavedra, C, Fernández-Clotet, A, Masamunt, M, Ricart, E, Rimola, J

“…Abstract Background Changes in the 3D volumetry of perianal fistulas measured by magnetic resonance (MR) could be an imaging biomarker of interest. The…”
Get full text

P456 Magnetic resonance enterography findings at week 46 after biological treatment predict long-term clinical outcomes in Crohn’s disease patients by Fernandez Clotet, A, Ordás, I, Masamunt, M C, Caballol, B, Rodriguez, S, Panés, J, Ricart, E, Rimola, J

“…Abstract Background Magnetic resonance enterography (MRE) provides an accurate evaluation of transmural lesions in Crohn’s Disease (CD). However, MRE findings…”
Get full text

DOP65 T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease by Gudiño, V, Cho, J W, Corraliza, A M, Caballol, B, Garrido-Trigo, A, Masamunt, M C, Ordás, I, Ricart, E, Hemberg, M, Panés, J, Salas, A

“…Abstract Background Perianal fistulizing disease (PFD) is a complication occurring in about 20% of Crohn’s Disease (CD) patients. It consists of the formation…”
Get full text

P697 De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice by Arenas, A, Moreta, M J, Ordás, I, Fernández-Clotet, A, Caballol, B, Gallego, M, Vara, A, Barastegui, R, Giner, A, Prieto, C, Masamunt, M C, Ricart, E

“…Abstract Background Combination therapy with an immunomodulator (IMM) and an anti-TNF agent (specifically infliximab) is recommended in Crohn’s disease (CD)…”
Get full text

P026 Differential effects of tofacitinib on macrophage activation may contribute to lack of response in ulcerative colitis patients by Melón-Ardanaz, E, Veny, M, Corraliza, A M, Garrido-Trigo, A, Gudiño, V, Moro, M, Sanzo-Machuca, Á, Esteller, M, Masamunt, M C, Caballol, B, Ordás, I, Fernández-Clotet, A, Ricart, E, Panés, J, Salas, A

“…Abstract Background We previously showed that ulcerative colitis (UC) patients refractory to tofacitinib present an increase in the activation and the…”
Get full text

P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes by Iborra, M, Caballol, B, Garrido, A, Huguet, J M, Mesonero, F, Ponferrada, A, Arias-García, L, Boscá-Watts, M M, Fernández-Prada, S J, Brunet-Mas, E, Gutierrez-Casbas, A, Ordás, I, Ruiz, L, García de la Filia, I, Escobar Ortiz, J, Sicilia, B, Ricart, E, Nos, P

“…Abstract Background Evidence suggests that subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) is capable to maintain clinical remission safely…”
Get full text

P471 Predictors of bowel damage in long term progression of Crohn’s disease by Fernandez Clotet, A, Panes, J, Ricart, E, Castro Poceiro, J, Masamunt, M C, Rodríguez, S, Caballol, B, Ordas, I, Rimola, J

“…Abstract Background Crohn’s disease is a chronic inflammatory bowel disorder that progresses to bowel damage over time. An image-based index, the Lémann Index,…”
Get full text

THU-123 - Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men by Rodríguez-Tajes, S., Perpiñan, E., Caballol, B., Lens, S., Mariño, Z., Costa, J., Vilella, A., del Pulgar, S.P., Forns, X., Koutsoudakis, G.

Get full text

Virological and clinical characterization of a hepatitis A outbreak in Barcelona involving primarily men who have sex with men by Rodríguez-Tajes, S., Perpiñan, E., Caballol, B., Lens, S., Mariño, Z., Costa, J., Vilella, A., del Pulgar, S.P., Forns, X., Koutsoudakis, G.

Get full text

P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU by Gros, B, Manceñido Marcos, N, Guardiola, J, Alonso Abreu, I, Rodríguez Lago, I, Alvarado, R, Ponferrada, Á, Orobitg Bernades, J, Argüelles-Arias, F, Mesonero, F, Guerra, I, Cañete, F, Madero, L, Borràs, P, Rodríguez, G E, Iborra, M, Castro, J, Caballero Mateos, A, Barreiro-de Acosta, M, Huguet Malavés, J M, Brunet-Mas, E, López Romero-Salazar, F, Caballol, B, Zabana, Y, Suria Bolufer, C, Soto, P, Castro, B, Marín, S, Porto-Silva, S, Benítez, J M, Gutierrez, A, Iglesias-Flores, E

“…Abstract Background Despite the established use of intravenous (IV) vedolizumab for treating inflammatory bowel disease (IBD), there's growing interest in…”
Get full text

OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia by Brunet, E, Selva, A, Bas-Cutrina, F, Brujats, A, Caballol, B, Gomez, B, Gonzalez, C, Busquets, D, Monfort, D, Vera, D P, Maristany, E, Cirera, G, Torres, G, Castro-Poceiro, J, Lopez, J, Gonzalez-Gonzalez, L, Marquez-Mosquera, L, Gallach, M, Esteve, M, Tremosa, G, Torra, S, Robles, V, Rodríguez-Lago, I, Calvet, X

“…Abstract Background Background: It has been postulated that early treatment of inflammatory bowel disease (IBD) is associated with a better long-term response…”
Get full text

P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study) by García, M J, Riestra, S, Amiot, A, Julsgaard, M, García de la Filia, I, Calafat, M, Aguas, M, de la Peña, L, Roig-Ramos, C, Caballol, B, Casanova, M J, Farkas, K, Boysen, T, Bujanda, L, Cuarán, C, Dobru, D, Fousekis, F, Gargallo-Puyuelo, C J, Savarino, E, Calvet, X, Huguet, J M, Kupcinskas, L, López-Cardona, J, Raine, T, van Oostrom, J, Gisbert, J P, Chaparro, M

“…Abstract Background The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis…”
Get full text

P575 Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results by Giordano, A, Rovira, M, Barastegui, R, Marín, P, Martínez, N, Fernández-Aviles, F, Suárez-Lledó, M, Doménech, A, Ordás, I, Fernández-Clotet, A, Caballol, B, Gallego, M, Vara, A, Masamunt, M C, Giner, A, Corraliza, A M, Panés, J, Salas, A, Ricart, E

“…Abstract Background Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with refractory Crohn’s disease [CD]…”
Get full text

P523 Effectiveness of biological treatments for inflammatory bowel disease in the elderly patients by Suarez Ferrer, C J, Mesonero, F, Caballol, B, Ballester, M P, Baston Rey, I, Castaño Garcia, A, Miranda Bautista, J, Saiz Chumillas, R, Benitez, J M, Sanchez Delgado, L, Lopez-Garcia, A, Rubin de Celix, C, Martin-Arranz, M D, Lopez Sanroman, A, Fernandez-Clotet, A, Merino Murgui, V, Calviño Suarez, C, Florez, P, Lobato Matilla, M E, Sicilia, B, Soto Escribano, P, Maroto Martin, C, Alonso Abreu, I, Melcarne, L, Elena, P G, Iyo, E, Elosua Gonzalez, A, Saiz, E, Hernandez Villalba, L, Perez Galindo, P, Torrealba Medina, L, Monsalve Alonso, S, Olmos Jerez, J A, Dueñas Sadornil, C, Barreiro-De Acosta, M

“…Abstract Background Biological treatments used for the treatment of inflammatory bowel disease (IBD) have demonstrated their efficacy and safety, although…”
Get full text

DOP04 Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU) by Bastón Rey, I, Calvino Suárez, C, Luque, A M, Caballol, B, Soutullo, C, Bravo, A, Castaño, A, Gros, B, Bernal, L, Diz Lois, M T, Alonso Galán, H, Cañete, F, Castro, B, Pérez Galindo, P, González Muñoza, C, El Hajra, I, Martínez Montiel, P, Alonso Abreu, I, Mesonero, F, González Vivo, M, Peries, L, Martín Arranz, E, Abril, C, Marín Jiménez, I, Baltar, R, Vicuna, M, Moreno, N, Brunet, E, Rubín de Célix, C, Fajardo, I, Cruz, N, Rojas Feria, M, Fernández Clotet, A, Gimeno, M, Zabana, Y, Suárez Ferrer, C, Rodríguez Lago, I, Barreiro de Acosta, M

“…Abstract Background Limited data is available of the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). The aim of…”
Get full text

P481 Profile of elderly patients in which biological drugs are used for the treatment of inflammatory bowel disease by Suarez Ferrer, C J, Mesonero, F, Caballol, B, Ballester, M P, Baston Rey, I, Castaño Garcia, A, Miranda Bautista, J, Saiz Chumillas, R, Benitez, J M, Sanchez Delgado, L, Lopez-Garcia, A, Rubin de Celio, C, Alonso Abreu, I, Melcarne, L, Plaza Santos, R, Marques Cami, M, Caballero Mateos, A, Gomez Diez, C, Calafat, M, Alonso Galan, H, Vega Vilaamil, P, Castro Sensosian, B, Guerro Moya, A, Rodriguez Diaz, C Y, Spicakova, K, Manceñido Marcos, N, Molina, G, De Castro, L, Rodriguez Angulo, A, Cuevas del Campo, L, Rodriguez Grau, M C, Ramirez, F, Gomez Pastrana, B, Gonzalez Partida, I, Botella Mateu, B, Peña Gonzalez, E, Iyo, E, Elosua Gonzalez, A, Mañosa Ciria, M, Barreiro-De Acosta, M

“…Abstract Background The use of biological drugs for the treatment of IBD in elderly patients is becoming more frequent in our environment. However, given the…”
Get full text

P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients? by Ferreiro Iglesias, R, Porto Silva, M S, Marín, S, Casanova, M J, Mañosa, M, González-Muñoza, C, de Francisco, R, Caballol, B, Arias, L, Piqueras, M, Zabana, Y, Rivero, M, Calvet, X, Mesonero, F, Varela Trastoy, P, Busta Nistal, R, Gomez Perosanz, R, Vega, P, Gonzalez Vivo, M, Iborra, M, Jimenez Marquez, L, Madero, L, Rodríguez-Lago, I, Rodriguez Gonzalez, M, Vera, I, Ponferrada Diaz, A, Vela, M, Torrealba, L, Van Domselaar, M, Iglesias, E, Gisbert, J P, Calafat, M, García-Planella, E, Perez-Martinez, I, Ricart, E, Sicilia, B, Mena, R, Nieto, L, Domenech, E, Barreiro-de Acosta, M

“…Abstract Background Ulcerative proctitis may have a mild and less aggressive course, although evidence is scarce because these patients are excluded from…”
Get full text

P410 Safety of biological drugs for inflammatory bowel disease in elderly patients by Suarez Ferrer, C J, Mesonero, F, Caballol, B, Ballester, M P, Baston Rey, I, Castaño Garcia, A, Miranda Bautista, J, Saiz Chumillas, R, Benitez, J M, Sanchez Delgado, L, Lopez-Garcia, A, Rubin de Celix, C, Lopez Sanroma, A, Martin-Arranz, M D, Fernández-Clotet, A, Merino Murgui, V, Calviño Suárez, C, Florez, P, Lobato matilla, M E, Sicilia, B, Soto Escribano, P, Maroto Martin, C, Alonso Abreu, I, Melcarne, L, Plaza Santos, R, Marques Cami, M, Caballero Mateos, A, Gómez Díez, C, Calafat, M, Alonso Galan, H, Vega Villaamil, P, Castro Senosiain, B, Guerro Moya, A, Rodriguez Diaz, C Y, Spicakova, K, Manceñido Marcos, N, Molina, G, De Castro, L, Mañosa Ciria, M, Barreiro-De Acosta, M

“…Abstract Background The most feared adverse events related to biological treatment in patients with inflammatory bowel disease (IBD) are the development of…”
Get full text

P349 Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU) by Bastón Rey, I, Calvino Suárez, C, Luque, A M, Caballol, B, Soutullo, C, Bravo, A, Castaño, A, Gros, B, Hurtado, A, Vázquez Rey, T, Alonso Galán, H, Cañete, F, Castro, B, Pérez Galindo, P, González Muñoza, C, El Hajra, I, Martínez Montiel, P, Alonso Abreu, I, Mesonero, F, González Vivo, M, Peries, L, Martín Arranz, E, Abril, C, Marín Jiménez, I, Baltar, R, Vicuña, M, Moreno, N, Brunet, E, Rodríguez Lago, I, Rubín de Célix, C, Fajardo, I, Cruz, N, Rojas Feria, M, Fernández Clotet, A, Gimeno, M, Zabana, Y, Suárez Ferrer, C, Barreiro de Acosta, M

“…Abstract Background Inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT) is associated with a greater complexity in their…”
Get full text